# Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

> **NCT01392469** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Sildenafil
- **DRUG:** Bosentan

## Key facts

- **NCT ID:** NCT01392469
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-20
- **Primary completion:** 2012-10-25
- **Final completion:** 2012-10-25
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392469, "Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01392469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*